At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,554 enrolled
Drug / intervention
Alogliptin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Alogliptin, Alogliptin placebo, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 1,554 participants across 90 sites in 19 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesAustralia, Brazil, Bulgaria, Chile, Croatia, Estonia, Guatemala, India, Israel, Latvia, Mexico, New Zealand, Peru, Romania, Russia, Serbia, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedMay 2006
Primary CompletionMar 2008
TodayJul 2026
First PostedMay 22, 2006
Enrollment StartMay 1, 2006
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.1 years ago
Interventions
Alogliptindrug
Alogliptin tablets.
Alogliptin placebodrug
Alogliptin placebo-matching tablets.
Pioglitazonedrug
Pioglitazone tablets.
Pioglitazone placebodrug
Pioglitazone placebo-matching tablets.